Search

Your search keyword '"B. Gonzalez-Farre"' showing total 13 results
Start Over Author "B. Gonzalez-Farre" Language undetermined
13 results on '"B. Gonzalez-Farre"'

1. 13P Analytical validation of HER2DX test for early-hER2+ breast cancer

Author

E. Sanfeliu Torres, M. Marín-Aguilera, P. Jares, G. Villacampa, E. Hernández-Illán, B. Gonzalez-Farre, F. Brasó-Maristany, P. Galván, O. Castillo, P. Blasco, V. Sirenko, Á. Aguirre, J.A. Puig-Butille, A. Vivancos, J. Matito, C.M. Perou, P. Villagrasa Gonzalez, A. Prat, J. Parker, and L. Pare Brunet

Subjects
Cancer Research, Oncology
Published
2023
Full Text
View/download PDF

4. 7P Independent validation of HER2DX ERBB2 mRNA score to predict HER2-positive (HER2+), HER2-low and HER2-0 status in breast cancer

Author

E. Sanfeliu Torres, G. Villacampa, T. Pascual, M. Oliveira, M.J. Vidal Losada, M. Bellet-Ezquerra, B. Gonzalez-Farre, J.A. Puig-Butille, P. Jares, S. Pernas Simon, C. Bueno Muiño, M. Martin Jimenez, P. Tarantino, A.G. Waks, E.A. Mittendorf, S.M. Tolaney, J. Cortés, A. Llombart Cussac, A. Prat, and F. Brasó-Maristany

Subjects
Cancer Research, Oncology
Published
2023
Full Text
View/download PDF

5. PEDIATRIC NODAL MARGINAL ZONE LYMPHOMA AND PEDIATRIC-TYPE FOLLICULAR LYMPHOMA SHARE A COMMON MOLECULAR PROFILE

Author

J. Salmeron-Villalobos, C. Egan, V. Borgmann, I. Müller, B. Gonzalez-Farre, J. Ramis-Zaldivar, D. Nann, O. Balagué, M. Lopez-Guerra, D. Colomer, I. Oschlies, W. Klapper, S. Glaser, Y. Ko, I. Bonzheim, R. Siebert, F. Fend, S. Pittaluga, E. Campo, I. Salaverria, E. Jaffe, and L. Quintanilla-Martinez

Subjects
Cancer Research, Oncology, Hematology
Published
2022
Full Text
View/download PDF

6. 132TiP HCB-ONC001 ELPIS TRIAL: Omission of surgery and sentinel lymph node dissection in clinically low-risk HER2-positive breast cancer with high HER2 addiction and a complete response following standard anti-HER2-based neoadjuvant therapy

Author

T. Pascual, N. Chic, O. Martinez Saez, E. Sanfeliu Torres, B. Adamo, I. Cebrecos, E. Mension, X. Bargalló, X. Caparros, S. Ganau, B. Gonzalez-Farre, M. Mollá, G. Oses, A.B. Rodriguez, B. Úbeda, M.J. Vidal Losada, S. Vidal-Siscart, M. Munoz, and A. Prat

Subjects
Oncology, Hematology
Published
2022
Full Text
View/download PDF

7. Abstract P5-11-04: Anti-proliferative effect of oral metronomic vinorelbine (mVNB) in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): A randomized, three-arm, window-of-opportunity study

Author

Salvador Blanch, J.A. Perez Fidalgo, Eva Ciruelos, B. Adamo, Xavier Gonzalez, Jordi Canes, B. Gonzalez Farre, Andreu Prat, T. Pascual, M. Bellet Ezquerra, A. López González, Laia Paré, Patricia Galván, L Murillo Jaso, Kepa Amillano, P. Gomez Pardo, Patricia Villagrasa, M.J. Mendez Vidal, Nerea Martinez, and V. Ortega Cebrian

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Window of opportunity, business.industry, HER2 negative, Anti proliferative, Vinorelbine, Internal medicine, medicine, business, Early breast cancer, medicine.drug
Abstract

BACKGROUND: The anti-proliferative effect of mVNB alone or in combination with endocrine therapy in patients with hormone receptor-positive/HER2- breast cancer (BC) has been scarcely addressed. METHODS: Postmenopausal women with untreated stage I-III BC were randomized (1:1:1) to receive 3 weeks of letrozole (LTZ) 2.5mg/day, oral mVNB 50mg 3 days/week or the combination. The 1ary objective was to evaluate, within PAM50 Luminal A/B disease, if the anti-proliferative effect of mVNB+LTZ was superior to monotherapy. An anti-proliferative effect was defined as the mean relative decrease of the PAM50 11-gene Proliferation Score in each arm. 2ary objectives included safety and the comparison of the anti-proliferative effect between arms. An unplanned analysis of stromal tumor infiltrating lymphocytes (sTILs) was performed. PAM50 analyses were performed using the nCounter®-based Breast Cancer 360TM panel. Changes in the expression of 790 genes/signatures tracking multiple biological processes from tumor cells and the microenvironment were evaluated within each arm using paired (surgery vs. baseline) univariate analyses. P-values were corrected for multiple comparisons using false discovery rate (FDR). RESULTS: A total of 61 patients were randomized and 54 paired samples (89%) were analyzed. Main patient characteristics were mean age 67, mean tumor size 1.7 cm, stage I (55.7%) and grade 1-2 (90%). Grade 3 toxicities occurred in 3.3% of cases. Baseline samples were Luminal A (72.3%) or B (27.7%). The anti-proliferative effect of mVNB+LTZ (-73.2%) was superior to both monotherapy arms combined (-49.9%; p=0.001) and mVNB (-19.1%; p CONCLUSIONS: mVNB is well-tolerated and presents antiproliferative activity alone and in combination with LTZ. The increase of activated CD8 T-cells or TILs observed with LTZ+mVNB opens the possibility of studying combinations with immunotherapy. Further investigation comparing these biological results with other metronomic schedules or combinations is warranted. Citation Format: Prat A, Adamo B, Pascual T, Perez Fidalgo JA, Blanch S, Martínez N, Gomez Pardo P, Lopez Gonzalez A, Murillo Jaso L, Amillano K, Vidal M, Paré L, Canes J, Galvan P, Gonzalez Farre B, Ortega Cebrián V, Gonzalez X, Bellet Ezquerra M, Villagrasa P, Ciruelos E. Anti-proliferative effect of oral metronomic vinorelbine (mVNB) in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): A randomized, three-arm, window-of-opportunity study [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-11-04.

Published
2019
Full Text
View/download PDF

8. 202TiP SOLTI-1805 TOT-HER3 trial: A window-of-opportunity trial of patritumab deruxtecan (HER3-DXd) in patients with treatment-naïve, early breast cancer

Author

M. Oliveira, J.M. Cejalvo Andujar, M. Margeli Vila, P. Tolosa Ortega, O. Martinez Saez, F.J. Salvador Bofill, J. Cruz Jurado, A.M. Luna Barrera, M.A. Arumi de Dios, M.J. Vidal Losada, J.A. Guerra, S. Pernas Simon, G. Villacampa Javierre, B. Gonzalez-farre, E. Sanfeliu Torres, A. Santhanagopal, C. Falato, J.M. Ferrero Cafiero, T. Pascual, and A. Prat

Subjects
Oncology, Hematology
Published
2022
Full Text
View/download PDF

9. LBA3 Patritumab deruxtecan (HER3-DXd) in early-stage HR+/HER2- breast cancer: Final results of the SOLTI TOT-HER3 window of opportunity trial

Author

A. Prat, C. Falato, L. Pare Brunet, O. Martinez Saez, J.M. Cejalvo Andujar, M. Margeli Vila, P. Tolosa, F.J. Salvador Bofill, J. Cruz Jurado, B. Gonzalez-Farre, E. Sanfeliu Torres, E.M. Ciruelos, M. Espinosa-Bravo, Y. Izarzugaza Peron, S. Pernas Simon, S. Esker, P-D. Fan, J.M. Ferrero Cafiero, T. Pascual, and M. Oliveira

Subjects
Oncology, Hematology
Published
2022
Full Text
View/download PDF

10. 108P Pathologic nodal positivity in patients with cT1-2 cN0 HER2+ breast cancer treated with upfront surgery or neoadjuvant anti-HER2-based therapy

Author

O. Martinez Saez, C. Hernando Melia, M. Rey, N. Chic, M.T.M. Martinez, I. Cebrecos, B. Bermejo De Las Heras, X. Bargalló, O. Burgués, S. Ganau, B. Úbeda, M. Mollá, S. Vidal-Siscart, E. Sanfeliu Torres, B. Gonzalez-Farre, M. Vidal, B. Adamo, M. Munoz, A. Prat, and J.M. Cejalvo Andujar

Subjects
Oncology, Hematology
Published
2022
Full Text
View/download PDF

12. Sentinel node after NeoAdjuvancy in node-positive breast cancer. SANA multicentric study

Author

M.J. Mendez Vidal, M. Vernet, Montse Muñoz, N. Sánchez, M. Mollà, I. Torras, M. Solà, G. Osés, I.Vives Rosello, Andreu Prat, A. Marsical, Xavier Bargalló, X.Caparrós Algarra, I.Alonso Vargas, B. Ubeda, S. Ganau, B. Gonzalez Farre, and Sergi Vidal-Sicart

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Breast cancer, business.industry, Internal medicine, Node (networking), medicine, Sentinel node, business, medicine.disease
Published
2020

13. Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): An open-label, randomized, three-arm, multicenter, window-of-opportunity study

Author

T. Pascual, Salvador Blanch, Patricia Galván, Nerea Martinez, V. Ortega Cebrian, M. Bellet Ezquerra, L. Murillo Juso, J.A. Perez Fidalgo, Xavier Gonzalez, B. Gonzalez Farre, Patricia Villagrasa, Jordi Canes, P. Gomez Pardo, M.J. Mendez Vidal, Andreu Prat, A. López González, Laia Paré, B. Adamo, Kepa Amillano, and Eva Ciruelos

Subjects
Oncology, Window of opportunity, medicine.medical_specialty, business.industry, HER2 negative, Hematology, Anti proliferative, Vinorelbine, Internal medicine, medicine, Open label, business, Early breast cancer, medicine.drug
Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results